Clinical trials in Le Chesnay-Rocquencourt – page 18

3 344 clinical trials in Le Chesnay-Rocquencourt, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Le Chesnay-Rocquencourt at a glance

3 344

clinical trials

Research sites1

Quick filters

3 344 trials in Le Chesnay-Rocquencourt

Open in trial search

Chronic cutaneous lupus erythematosus+2

Recruiting

Phase 3 Study of Enpatoran in Patients with Active Cutaneous Lupus Erythematosus (with or without Systemic Disease)

Investigational

Phase 3 Study of Enpatoran in Patients with Active Cutaneous Lupus Erythematosus (with or without Systemic Disease)

Investigational

France

Participants:18–64 years · 65+ years
Substances:Enpatoran hemihydrate
Sponsor:Merck Healthcare KGaA

Contact Research Centre

Pancreatic carcinoma metastatic

Recruiting

Randomized Study of INCB161734 Plus Standard Chemotherapy Drug Combination in Untreated KRAS G12D Metastatic Pancreatic Ductal Adenocarcinoma Patients

Registered drug

Randomized Study of INCB161734 Plus Standard Chemotherapy Drug Combination in Untreated KRAS G12D Metastatic Pancreatic Ductal Adenocarcinoma Patients

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Incyte Corp.

Contact Research Centre

Bladder cancer

Recruiting

Study of Enfortumab Vedotin and Pembrolizumab for Bladder Preservation in Patients with Muscle‑Invasive Bladder Cancer

Registered drugNo placebo

Study of Enfortumab Vedotin and Pembrolizumab for Bladder Preservation in Patients with Muscle‑Invasive Bladder Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Enfortumab Vedotin
Sponsor:Astellas Pharma Global Development Inc.

Contact Research Centre

Hereditary angioedema

Recruiting

Long‑Term Safety Study of ADX‑324 in Participants with Hereditary Angioedema (Phase 3 Extension)

Investigational

Long‑Term Safety Study of ADX‑324 in Participants with Hereditary Angioedema (Phase 3 Extension)

Investigational

France

Participants:18–64 years · 65+ years
Substances:ADX-324
Sponsor:Adarx Pharmaceuticals Inc.

Contact Research Centre

Gastric cancer+1

Recruiting

Study of AZD0901 (sonesitatug vedotin) with capecitabine ± rilvegostomig in adults with advanced stomach or esophageal cancer (Claudin‑18.2‑positive, HER2‑negative)

Registered drugNo placebo

Study of AZD0901 (sonesitatug vedotin) with capecitabine ± rilvegostomig in adults with advanced stomach or esophageal cancer (Claudin‑18.2‑positive, HER2‑negative)

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:AZD0901
Sponsor:AstraZeneca AB

Contact Research Centre

Glomerulonephritis membranoproliferative+1

Recruiting

Effectiveness and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative Glomerulonephritis

Registered drugNo placebo

Effectiveness and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative Glomerulonephritis

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Pegcetacoplan
Sponsor:Swedish Orphan Biovitrum AB (publ)

Contact Research Centre

Polymyalgia rheumatica

Recruiting

Efficacy and safety of sarilumab plus prednisone versus prednisone alone in adults with early polymyalgia rheumatica

Registered drug

Efficacy and safety of sarilumab plus prednisone versus prednisone alone in adults with early polymyalgia rheumatica

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Prednisone
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

B-cell type acute leukaemia

Recruiting

Study of MK-1045 versus blinatumomab with tocilizumab in patients with relapsed or refractory B-cell acute lymphoblastic leukemia

Registered drugNo placebo

Study of MK-1045 versus blinatumomab with tocilizumab in patients with relapsed or refractory B-cell acute lymphoblastic leukemia

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Blinatumomab
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Non-small cell lung cancer

Recruiting

Study of MK-1084 plus durvalumab versus placebo plus durvalumab in patients with locally advanced KRAS G12C‑mutant non‑small cell lung cancer after chemoradiotherapy

Registered drug

Study of MK-1084 plus durvalumab versus placebo plus durvalumab in patients with locally advanced KRAS G12C‑mutant non‑small cell lung cancer after chemoradiotherapy

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Durvalumab
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Oesophageal adenocarcinoma

Recruiting

Study of denikitug alone or with drug combination in adults with HER2‑negative metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma

Registered drugNo placebo

Study of denikitug alone or with drug combination in adults with HER2‑negative metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Denikitug
Sponsor:Gilead Sciences Inc.

Contact Research Centre

Acute myeloid leukaemia

Recruiting

Venetoclax added to fludarabine, cytarabine and gemtuzumab ozogamicin (drug combination) in children with relapsed acute myeloid leukemia

Registered drugNo placebo

Venetoclax added to fludarabine, cytarabine and gemtuzumab ozogamicin (drug combination) in children with relapsed acute myeloid leukemia

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years
Substances:Azacitidine
Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Contact Research Centre

Malignant mast cell neoplasm

Recruiting

Phase 1/2 Study of VS-7375 with Drug Combination in Patients with Advanced KRAS G12D‑Mutated Solid Tumors

Registered drugNo placebo

Phase 1/2 Study of VS-7375 with Drug Combination in Patients with Advanced KRAS G12D‑Mutated Solid Tumors

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Verastem Inc.

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Le Chesnay-Rocquencourt

What the registry says about research in the country

01 Cardiology & Respiratory Medicine

Clinical trials focusing on acute myocardial infarction pain management and innovative treatments for severe asthma. Research includes evaluation of novel pain-relief methods and assessment of treatment discontinuation strategies.

Pain management in heart attacks
Asthma treatment optimization
Heart failure management

Studies also examine beta-blocker discontinuation in patients with recovered heart function.

02 Oncology & Hematology

Extensive research in blood cancers, including multiple myeloma, acute myeloid leukemia, and various lymphomas. Studies evaluate novel drug combinations and treatment strategies.

Blood cancer therapies
Leukemia treatments
Breast cancer management

Investigations include targeted therapies and personalized treatment approaches for various cancer types.

03 Pediatric & Infectious Diseases

Research focusing on respiratory syncytial virus (RSV) prevention in infants and children. Studies evaluate new protective treatments and their safety profiles.

RSV prevention
Infant protection studies
Immunotherapy research

Trials include assessment of novel medications for preventing severe respiratory infections in vulnerable populations.

Back to France All countries